Sage's postpartum depression treatment benefits outweigh risk: FDA panel
(Reuters) – The benefits of Sage Therapeutics Inc’s experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said on Friday. The panel voted 17 to 1 in favor of the injectable treatment, Zulresso, that aims to treat major episodes of depression during pregnancy or within 4 weeks… Read More »